Regeneron tore its manufacturing processes and supply chain apart in an investigation after a spike in a rare side effect was discovered with some patients taking its top-selling sight drug Eylea. While the company says it has found no issues with the drug or its manufacturing, it has found an association between the problem and some Becton Dickinson syringes that were distributed in the U.S.Original Article
Regeneron ties spike in Eylea side effect to syringes in some kits in the U.S.
